Studies on Combination of Platinum Drugs Cisplatin and Oxaliplatin with Phytochemicals Anethole and Curcumin in Ovarian Tumour Models

被引:0
|
作者
Nessa, Meher U.
Beale, Philip [2 ]
Chan, Charles [3 ]
Yu, Jun Q.
Huq, Fazlul [1 ]
机构
[1] Univ Sydney, Discipline Biomed Sci, Sch Med Sci, Sydney Med Sch, Lidcombe, NSW 1825, Australia
[2] Concord Hosp, Sydney Canc Ctr, Concord, NSW, Australia
[3] Concord Hosp, Dept Pathol, Concord, NSW, Australia
关键词
Drug resistance; drug combination; anethole; curcumin; cisplatin; oxaliplatin; NF-KAPPA-B; INDUCED APOPTOSIS; GENE-EXPRESSION; CANCER CELLS; SYNERGISM; INHIBITION; ACTIVATION; CARCINOMA; PATHWAYS; SURVIVAL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemopreventative phytochemicals having antitumour and antioxidant properties can overcome problems of chemoresistance and nonspecific toxicity towards normal cells that are associated with platinum-based chemotherapy against cancer. These agents exert their effects by bringing into play numerous cellular proteins that in turn affect multiple steps in pathways leading to tumourigenesis. In this study, combinations of two cytotoxic phytochemicals anethole and curcumin were applied in binary combination with platinum drugs cisplatin and oxaliplatin to three epithelial ovarian cancer cell lines: A2780 (parent), A2780(cisR) (cisplatin-resistant) and A2780(ZD0473R) (ZD0473-resistant). Cell viability was quantified using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction assay and the combined drug action was analyzed based on the equations derived by Chou and Talalay (1984). Greatest synergism was observed when the phytochemical was added first followed by the platinum drug 2 h later and additiveness to antagonism in combined drug action was observed when the two compounds were administered as a bolus. If confirmed in vivo, the appropriate sequenced combinations of platinum with the phytochemicals may provide a means of overcoming drug resistance.
引用
收藏
页码:4843 / 4850
页数:8
相关论文
共 50 条
  • [41] INVITRO AND INVIVO EVALUATION OF THE COMBINATION OF CISPLATIN AND ITS ANALOG CARBOPLATIN FOR PLATINUM DOSE INTENSIFICATION IN OVARIAN-CARCINOMA
    DITTRICH, C
    SEVELDA, P
    BAUR, M
    MARTH, C
    HUDEC, M
    VAVRA, N
    GRUNT, T
    FAZENY, B
    SALZER, H
    CANCER, 1993, 71 (10) : 3082 - 3090
  • [42] Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models
    Pisano, C.
    Vesci, L.
    Fodera, R.
    Ferrara, F. F.
    Rossi, C.
    De Cesare, M.
    Zuco, V.
    Pratesi, G.
    Supino, R.
    Zunino, F.
    ANNALS OF ONCOLOGY, 2007, 18 (09) : 1500 - 1505
  • [43] Comparison and modulation of mechanisms of action between cisplatin and oxaliplatin treatment in colic cancer cells: an approach to identify acquired resistance to platinum drugs
    Moretto, J.
    Belon, J. P.
    Chauffert, B.
    Bouyer, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 116 - 117
  • [44] Synergism from combination of targeted therapy with tumor active phytochemicals in ovarian tumor models and changes in protein expression
    Huq, Fazlul
    CANCER RESEARCH, 2015, 75
  • [45] Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants
    Ramakumar Tummala
    Paula Diegelman
    Suzanne Hector
    Debora L. Kramer
    Kimberly Clark
    Patricia Zagst
    Gerald Fetterly
    Carl W. Porter
    Lakshmi Pendyala
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 401 - 414
  • [46] Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer
    Seliger, Gregor
    Mueller, Lutz P.
    Kegel, Thomas
    Kantelhardt, Eva. J.
    Grothey, Axel
    Grosse, Regina
    Strauss, Hans-Georg
    Koelbl, Heinz
    Thomssen, Christoph
    Schmoll, Hans-Joachim
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (08) : 1446 - 1453
  • [47] Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
    Douwes F.
    Bogovič J.
    Douwes O.
    Migeod F.
    Grote C.
    International Journal of Clinical Oncology, 2004, 9 (2) : 85 - 91
  • [48] Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma:: An investigator-originated compassionate-use experience
    Faivre, S
    Kalla, S
    Cvitkovic, E
    Bourdon, O
    Hauteville, D
    Dourte, LM
    Bensmaïne, MA
    Itzhaki, M
    Marty, M
    Extra, JM
    ANNALS OF ONCOLOGY, 1999, 10 (09) : 1125 - 1128
  • [49] Comparative studies of oxaliplatin-based platinum(IV) complexes in different in vitro and in vivo tumor models
    Goeschl, Simone
    Schreiber-Brynzak, Ekaterina
    Pichler, Verena
    Cseh, Klaudia
    Heffeter, Petra
    Jungwirth, Ute
    Jakupec, Michael A.
    Berger, Walter
    Keppler, Bernhard K.
    METALLOMICS, 2017, 9 (03) : 309 - 322
  • [50] In vitro combination studies with the sterically hindered platinum drug, ZDO473, in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers, PM
    Boxall, F
    Allott, CP
    Stephens, T
    Kelland, LR
    CLINICAL CANCER RESEARCH, 2000, 6 : 4537S - 4537S